Silence Therapeutics plc (SLNCF)

Market Cap	298.05M
Revenue (ttm)	25.83M
Net Income (ttm)	-64.54M
Shares Out	n/a
EPS (ttm)	-1.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,017
Open	1.600
Previous Close	1.600
Day's Range	1.600 - 1.600
52-Week Range	0.499 - 6.000
Beta	1.34
RSI	48.70
Earnings Date	Nov 7, 2025

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, includin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 116
• Stock Exchange: OTCMKTS
• Ticker Symbol: SLNCF

Financial Performance

In 2024, Silence Therapeutics's revenue was $43.26 million, an increase of 36.71% compared to the previous year's $31.64 million. Losses were -$45.31 million, -16.45% less than in 2023.